Yantai Dongcheng Pharmaceutical Co Ltd (002675) - Total Assets

Latest as of September 2025: CN¥9.29 Billion CNY ≈ $1.36 Billion USD

Based on the latest financial reports, Yantai Dongcheng Pharmaceutical Co Ltd (002675) holds total assets worth CN¥9.29 Billion CNY (≈ $1.36 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002675 net asset value for net asset value and shareholders' equity analysis.

Yantai Dongcheng Pharmaceutical Co Ltd - Total Assets Trend (2008–2024)

This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.

Yantai Dongcheng Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Yantai Dongcheng Pharmaceutical Co Ltd's total assets of CN¥9.29 Billion consist of 29.7% current assets and 70.3% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 8.8%
Accounts Receivable CN¥948.72 Million 11.0%
Inventory CN¥646.22 Million 7.5%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥518.23 Million 6.0%
Goodwill CN¥2.50 Billion 29.0%

Asset Composition Trend (2008–2024)

This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Yantai Dongcheng Pharmaceutical Co Ltd (002675) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Yantai Dongcheng Pharmaceutical Co Ltd's current assets represent 29.7% of total assets in 2024, a decrease from 69.0% in 2008.
  • Cash Position: Cash and equivalents constituted 8.8% of total assets in 2024, up from 5.4% in 2008.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 5.0% in 2008.
  • Asset Diversification: The largest asset category is goodwill at 29.0% of total assets.

Yantai Dongcheng Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Yantai Dongcheng Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Yantai Dongcheng Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.71 1.58 1.55
Quick Ratio 1.33 1.20 1.04
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.19 Billion CN¥970.54 Million CN¥1.05 Billion

Yantai Dongcheng Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Yantai Dongcheng Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.52
Latest Market Cap to Assets Ratio 0.18
Asset Growth Rate (YoY) 6.8%
Total Assets CN¥8.63 Billion
Market Capitalization $1.57 Billion USD

Valuation Analysis

Below Book Valuation: The market values Yantai Dongcheng Pharmaceutical Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Yantai Dongcheng Pharmaceutical Co Ltd's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Yantai Dongcheng Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual total assets of Yantai Dongcheng Pharmaceutical Co Ltd from 2008 to 2024.

Year Total Assets Change
2024-12-31 CN¥8.63 Billion
≈ $1.26 Billion
+6.83%
2023-12-31 CN¥8.08 Billion
≈ $1.18 Billion
-1.16%
2022-12-31 CN¥8.18 Billion
≈ $1.20 Billion
+6.80%
2021-12-31 CN¥7.66 Billion
≈ $1.12 Billion
+3.56%
2020-12-31 CN¥7.39 Billion
≈ $1.08 Billion
+1.35%
2019-12-31 CN¥7.29 Billion
≈ $1.07 Billion
+4.70%
2018-12-31 CN¥6.97 Billion
≈ $1.02 Billion
+32.13%
2017-12-31 CN¥5.27 Billion
≈ $771.63 Million
+23.55%
2016-12-31 CN¥4.27 Billion
≈ $624.53 Million
+67.51%
2015-12-31 CN¥2.55 Billion
≈ $372.84 Million
+82.86%
2014-12-31 CN¥1.39 Billion
≈ $203.89 Million
+13.42%
2013-12-31 CN¥1.23 Billion
≈ $179.77 Million
+12.88%
2012-12-31 CN¥1.09 Billion
≈ $159.26 Million
+141.19%
2011-12-31 CN¥451.24 Million
≈ $66.03 Million
+25.62%
2010-12-31 CN¥359.19 Million
≈ $52.56 Million
+34.55%
2009-12-31 CN¥266.96 Million
≈ $39.07 Million
+36.84%
2008-12-31 CN¥195.09 Million
≈ $28.55 Million
--

About Yantai Dongcheng Pharmaceutical Co Ltd

SHE:002675 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.57 Billion
CN¥10.71 Billion CNY
Market Cap Rank
#7207 Global
#1701 in China
Share Price
CN¥12.99
Change (1 day)
-2.48%
52-Week Range
CN¥12.24 - CN¥18.29
All Time High
CN¥27.09
About

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluro… Read more